Alexandra Byrne

6 days ago | precisionmedicineonline.com | Alexandra Byrne

NEW YORK – Mice have served as living proxies for testing the activity of investigational drugs before starting human clinical trials for more than 85 years. But now, the US Food and Drug Administration (FDA) wants to phase out animal testing in the development of monoclonal antibodies and other drugs. The rise of precision medicine has coincided with the development of non-animal preclinical testing tools that attempt to mimic human biology.

1 week ago | precisionmedicineonline.com | Alexandra Byrne

NEW YORK – The addition of a radio enhancer may increase the number of locally advanced or borderline unresectable pancreatic cancer patients who respond to radiation therapy, according to Phase I study results announced Monday by French biotech company Nanobiotix. In the Phase I trial, Nanobiotix evaluated a novel radio enhancer, NBTXR3, in patients with locally advanced or borderline unresectable pancreatic ductal adenocarcinoma.

2 weeks ago | precisionmedicineonline.com | Alexandra Byrne

NEW YORK – Amid questions over the financial impact of tariffs and Medicare Part D reform, Pfizer did not meet the consensus Wall Street revenue expectations in the first quarter of 2025 but saw continued sales growth within its oncology segment. As the company navigates an uncertain trade landscape, it will also face generic competition for several drugs in its pipeline.

2 weeks ago | precisionmedicineonline.com | Alexandra Byrne

NEW YORK – Revolution Medicine's zoldonrasib, a drug targeting the KRAS-G12D mutation in patients with non-small cell lung cancer, shrunk tumors in around 60 percent of patients in a clinical trial.

2 weeks ago | precisionmedicineonline.com | Alexandra Byrne

NEW YORK – Research and development of precision medicines usually happens faster than community oncologists can keep up. It wasn't that long ago that Dong Kim was in medical school using next-generation sequencing for research. In the decade since, Kim has become an oncologist at Maryland Oncology Hematology in Silver Spring, molecular testing and NGS has become cheaper and more accessible, and new treatment options have proliferated.